Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis

Journal of the Neurological Sciences

Volumn 267, Issue 1-2, 2008, Pages 28-35

  Zivadinov, Robert ^a,b   Zorzon, Marino ^a   De Masi, Roberto ^a   Nasuelli, Davide ^a   Cazzato, Giuseppe ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b JACOBS NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Confluence; Multiple sclerosis; Steroid therapy; T2 lesions

Indexed keywords

METHYLPREDNISOLONE; PREDNISONE;

ADULT; AGED; ARTICLE; BRAIN DAMAGE; BRAIN SIZE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DRUG EFFECT; DRUG PULSE THERAPY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; CENTRAL NERVOUS SYSTEM; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NERVE FIBERS, MYELINATED; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 39049089920     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2007.09.025     Document Type: Article

References (30)

1. Zivadinov R., Rudick R.A., De Masi R., Nasuelli D., Ukmar M., Pozzi-Mucelli R.S., et al. Effects of intravenous methylprednisolone on brain atrophy in relapsing-remitting multiple sclerosis. Neurology 57 (2001) 1239-1247
2. Goodkin D.E., Kinkel R.P., Weinstock-Guttman B., VanderBrug-Medendorp S., Secic M., Gogol D., et al. A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology 51 (1998) 239-245
3. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 12 (1983) 227-231
4. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
5. Zivadinov R., Sepcic J., Nasuelli D., De Masi R., Bragadin L.M., Tommasi M.A., et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 70 (2001) 773-780
6. Zivadinov R., DeMasi R., Nasuelli D., Bragadin L.M., Ukmar M., Pozzi-Mucelli R.S., et al. Magnetic resonance imaging techniques and cognitive impairment in early phase of relapsing-remitting multiple sclerosis. Neuroradiology 43 (2001) 272-278
7. Wang L., Lai H.M., Thompson A.J., and Miller D.H. Survey of the distribution of lesion size in multiple sclerosis: implication for the measurement of total lesion load. J Neurol Neurosurg Psychiatry 63 (1997) 452-455
8. Simon J.H., Jacobs L.D., Campion M., Wende K., Simonian N., Cookfair D.L., et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann Neurol 43 (1998) 79-87
9. Sorensen P.S., Wanscher B., Jensen C.V., Schreiber K., Blinkenberg M., Ravnborg M., et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50 (1998) 1273-1281
10. Oliveri R.L., Sibilia G., Valentino P., Russo C., Romeo N., and Quattrone A. Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Neurology 51 (1998) 1689-1697
11. Li D.K.B., Paty D.W., and and the UBC MS/MRI Analysis Research Group and the PRISMS Study Group. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon beta-1a in relapsing-remitting MS. Ann Neurol 46 (1999) 197-206
12. Miller D.H., Molyneux P.D., Barker G.J., MacManus D.G., Moseley I.F., and Wagner K. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis. Ann Neurol 46 (1999) 850-859
13. Kesselring J., Miller D.H., MacManus D.G., Johnson G., Milligan N.M., Scolding N., et al. Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone. J Neurol Neurosurg Psychiatry 52 (1989) 14-17
14. Saida K., Zhigang Z., Ozawa K., Konishi T., and Saida T. Long-term open-trial of mizoribine with prednisolone in 24 patients with multiple sclerosis: safety, clinical and magnetic resonance imaging outcome. Intern Med 38 (1999) 636-642
15. Filippi M., Rovaris M., Capra R., Gasperini C., Prandini F., Martinelli V., et al. Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology. J Neurol Neurosurg Psychiatry 67 (1999) 386-389
16. Brex P.A., Molyneux P.D., Smiddy P., Barkhof F., Filippi M., Yousry T.A., et al. The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS. Neurology 57 (2001) 2185-2190
17. Uhlenbrock D., Herbe E., Seidel D., and Gehlen W. One-year MR imaging follow-up of patients with multiple sclerosis under cortisone therapy. Neuroradiology 31 (1989) 3-7
18. Miller D.H., Thompson A.J., Morrissey S.P., MacManus D.G., Moore S.G., Kendall B.E., et al. High-dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 55 (1992) 450-453
19. Barkhof F., Tas M.W., Frequin S.T., Scheltens P., Hommes O.R., Nauta J.J., et al. Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. Neuroradiology 36 (1994) 382-387
20. Gasperini C., Pozzilli C., Bastianello S., Koudriavtseva T., Colleluori A., Millefiorini E., et al. The influence of clinical relapses and steroid therapy on the development of Gd-enhancing lesions: a longitudinal MRI study in relapsing-remitting multiple sclerosis patients. Acta Neurol Scand 95 (1997) 201-207
21. Kapoor R., Miller D.H., Jones S.J., Plant G.T., Brusa A., Gass A., et al. Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology 50 (1998) 230-237
22. Barkhof F., Hommes O.R., Scheltens P., and Valk J. Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 41 (1991) 1219-1222
23. Yong V.W. Differential mechanisms of action of interferon-beta and glatiramer aetate in MS. Neurology 59 (2002) 802-808
24. Inglese M., vanWaesberghe J.H., Rovaris M., Beckmann K., Barkhof F., Hahn D., et al. The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS. Neurology 60 (2003) 853-860
25. Sarchielli P., Presciutti O., Tarducci R., Gobbi G., Alberti A., Pelliccioli G.P., et al. 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study. J Neurol Neurosurg Psychiatry 64 (1998) 204-212
26. Richert N.D., Ostuni J.L., Bash C.N., Leist T.P., McFarland H.F., and Frank J.A. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Mult Scler 7 (2001) 49-58
27. Pavelko K.D., VanEngelen B.G., and Rodriguez M. Acceleration in the rate of CNS remyelination in lysolecithin induced demyelination. J Neurosci 18 (1998) 2498-2505
28. Ghatak N.R., Leshner R.T., Price A.C., and Felron W.L. Remyelination in the human central nervous system. J Neuropathol Exp Neurol 48 (1989) 507-518
29. Filippi M., Horsfield M.A., Ader H.J., Barkhof F., Bruzzi P., Evans A., et al. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol 43 (1998) 499-506
30. Markovic-Plese S., and McFarland H.F. Immunopathogenesis of the multiple sclerosis lesion. Curr Neurol Neurosci Rep 1 (2001) 257-262